3 case studies on how to characterize challenging drug discovery targets — membrane proteins, peptide libraries, and PROTACs
A caveat to a successful pharmaceutical industry in which many effective drugs have already been…
Dianthus
The NanoTemper Story – Chapter 5: The Dianthus
Almost as soon as the Monolith launched, the handful of people that made up NanoTemper…
3 big takeaways from SLAS on the future of automation and screening
5,200 researchers, representing all of life sciences, gathered in San Diego in late January to…
When aptamers are the better choice over mAbs
Monoclonal antibodies (mAbs) have become the molecule of choice when highly specific molecular recognition is…
6 ingredients for a successful fragment library
Fragment-based drug discovery (FBDD) has become a major strategy to derive novel lead candidates in…
PROTACs: the game-changing technology that promises to tackle “undruggable” proteins
Almost all pharmaceutical drugs today act by binding to disease-causing proteins and inhibiting their activity.…
5 things you must do while in Liverpool for ELRIG Drug Discovery
Here’s how to make your trip unforgettable. 1. Immerse yourself in Liverpool’s…
5 things you must do in Barcelona while at SLAS Europe (according to a local)
Here’s how to make your trip memorable. 1. Be awe-inspired at La…
Great things start small and so does the discovery of drug candidates
The famous painter Vincent Van Gogh once said, “Great things are done by a series…